As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Larimar Therapeutics, Inc. The largest reported stake is James E. Flynn's, at 34.41%. 9 filings are on record since July 31, 2025 (Schedule 13D/A, March 2, 2026).
Sell to companies like Larimar Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: Blue Owl Capital Holdings LP · Percent: 9.99% · SCHEDULE 13G/A
- · Holder: Millennium Management LLC · Percent: 3.5% · SCHEDULE 13G/A
- · Holder: James E. Flynn · Percent: 34.41% · SCHEDULE 13D/A
- · Holder: RA Capital Management, L.P. · Percent: 0% · SCHEDULE 13G/A
- · Holder: Blue Owl Capital Holdings LP · Percent: 9.99% · SCHEDULE 13G/A
Larimar Therapeutics, Inc. has 9 Schedule 13D or 13G filings on record since 2025-07-31. 2 holders' latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 34.41% | 35,667,474 | SCHEDULE 13D/A, 2026-03-02 | 2026-02-27 | |
| Blue Owl Capital Holdings LP | 9.99% | 10,739,492 | SCHEDULE 13G/A, 2026-05-14 | 2026-03-31 |
| Opaleye Management, Inc. | 4.8% | 4,110,000 | SCHEDULE 13G, 2025-08-29 | 2025-08-29 |
| Millennium Management LLC | 3.5% | 3,625,278 | SCHEDULE 13G/A, 2026-04-30 | 2026-03-31 |
| Janus Henderson Group Plc | 0% | 0 | SCHEDULE 13G/A, 2025-08-14 | 2025-03-31 |
| RA Capital Management, L.P. | 0% | 0 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
Holding shares or following this stake? See who's behind Larimar Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Larimar Therapeutics, Inc. and the records around it.
Larimar Therapeutics, Inc. elsewhere on the record
- Leadership changes Sep 2026
- Who owns it
Companies that share a holder
- Blue Owl Capital Holdings LP also filed stake reports on 10 other companies: Context Therapeutics Inc. (Aug 2026), enGene Therapeutics Inc. (Aug 2026), Aktis Oncology, Inc. (May 2026)
- Opaleye Management, Inc. also filed stake reports on 12 other companies: Codexis, Inc. (Nov 2026), Gossamer Bio, Inc. (Nov 2026), Pasithea Therapeutics Corp. (Nov 2026)
- Deerfield Private Design Fund III, L.P. also filed stake reports on 19 other companies: Climb Bio, Inc. (Oct 2026), Cogent Biosciences, Inc. (Aug 2026), Enhabit, Inc. (Aug 2026)
Watch Larimar Therapeutics, Inc.
Get an email when Larimar Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Larimar Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Larimar Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Larimar Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
10 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Purpose of Transaction (Item 4)
James E. Flynn
Item 4 of the Schedule 13D is hereby amended by adding the following: Each Fund acquired its February 2026 Shares for investment purposes in an underwritten offering conducted by the Company (the "February 2026 Offering") pursuant to the Prospectus Supplement, dated as of February 25, 2026, to the Issuer's Prospectus, dated as of May 24, 2024 (the "February 2026 Offering").Item 4 of the SCHEDULE 13D/A filed 2026-03-02
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-31 | James E. Flynn | 35.81% | SCHEDULE 13D/A |
| 2025-08-14 | Janus Henderson Group Plc | 0% | SCHEDULE 13G/A |
| 2025-08-29 | Opaleye Management, Inc. | 4.8% | SCHEDULE 13G |
| 2025-11-06 | Millennium Management LLC | 5.8% | SCHEDULE 13G/A |
| 2026-02-12 | Blue Owl Capital Holdings LP | 9.99% | SCHEDULE 13G/A |
| 2026-02-17 | RA Capital Management, L.P. | 0% | SCHEDULE 13G/A |
| 2026-03-02 | James E. Flynn | 34.41% | SCHEDULE 13D/A |
| 2026-04-30 | Millennium Management LLC | 3.5% | SCHEDULE 13G/A |
| 2026-05-14 | Blue Owl Capital Holdings LP | 9.99% | SCHEDULE 13G/A |
Questions about who owns Larimar Therapeutics, Inc.
Who owns Larimar Therapeutics, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Larimar Therapeutics, Inc.: James E. Flynn (34.41%, Schedule 13D/A, filed 2026-03-02) and Blue Owl Capital Holdings LP (9.99%, Schedule 13G/A, filed 2026-05-14).
Who are the largest shareholders of Larimar Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Larimar Therapeutics, Inc. on this page are James E. Flynn (34.41%) and Blue Owl Capital Holdings LP (9.99%).
When did James E. Flynn buy into Larimar Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from James E. Flynn on this page is the Schedule 13D/A, filed 2025-07-31, reporting 35.81%; its latest, Schedule 13D/A filed 2026-03-02, reports 34.41%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 9 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Larimar Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 29, 2026 | Leadership change: John B. Harlow appointed, Chief Operating Officer | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Larimar Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.